Security
enVVeno Medical Corporation Warrant 02/11/2026 · NVNBW
NVNBWOTCWarrantHistorical · closed Feb 11, 2026CIK 1661053Updated Oct 30, 2026
Name history
Hancock Jaffe Laboratories, Inc. · through Sep 22, 2021
Current security for this SEC filerNVNO · NASDAQ
NVNBW price & chart
Historical security
This listing closed Feb 11, 2026. Live provider charts are shown only for current listings.
Current security: NVNO
About the company
enVVeno Medical (NASDAQ: NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
10-Q filing
Regulation FD Disclosure
Items 7.01, 9.01
4 filing
144 filing
10-Q filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 32,352,000Source | 50,390,000Source | 22,660,000Source | 36,577,000Source | 40,995,000Source | 26,097,000Source | 40,577,000Source | 44,829,000Source | 29,562,000Source | 44,954,000Source | 48,635,000Source | 41,661,000Source |
| Property, Plant and Equipment, NetUSD | 82,000Source | 218,000Source | 78,000Source | 113,000Source | 252,000Source | 16,000Source | 142,000Source | 289,000Source | 51,000Source | 182,000Source | 334,000Source | 521,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,544,000Source | 17,915,000Source | 2,841,000Source | 2,044,000Source | 2,380,000Source | 2,597,000Source | 2,937,000Source | 2,314,000Source | 3,065,000Source | 1,754,000Source | 3,620,000Source | 4,555,000Source |
| Assets, CurrentUSD | 31,499,000Source | 49,051,000Source | 22,082,000Source | 35,604,000Source | 39,536,000Source | 25,489,000Source | 39,479,000Source | 43,248,000Source | 28,826,000Source | 43,734,000Source | 46,923,000Source | 39,436,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 547,000Source | 672,000Source | 596,000Source | 462,000Source | 469,000Source | 559,000Source | 538,000Source | 306,000Source | 614,000Source | 581,000Source | 511,000Source | 392,000Source |
| Operating Lease, Right-of-Use AssetUSD | 740,000Source | 1,090,000Source | 469,000Source | 829,000Source | 1,176,000Source | 561,000Source | 925,000Source | 1,261,000Source | 654,000Source | 1,007,000Source | 1,347,000Source | 1,673,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 2,905,000Source | 3,020,000Source | 1,990,000Source | 3,520,000Source | 2,577,000Source | 2,350,000Source | 2,270,000Source | 2,460,000Source | 2,432,000Source | 2,795,000Source | 2,435,000Source | 2,932,000Source |
| Stockholders’ equity: | ||||||||||||
| Additional Paid in CapitalUSD | 197,038,000Source | 192,996,000Source | 199,446,000Source | 196,109,000Source | 178,402,000Source | 198,923,000Source | 194,665,000Source | 177,397,000Source | 198,457,000Source | 194,014,000Source | 176,236,000Source | 145,249,000Source |
| Retained Earnings (Accumulated Deficit)USD | -167,591,000Source | -145,626,000Source | -178,776,000Source | -163,052,000Source | -139,984,000Source | -175,176,000Source | -156,358,000Source | -135,028,000Source | -171,327,000Source | -151,855,000Source | -130,036,000Source | -106,520,000Source |
| Stockholders' Equity Attributable to ParentUSD | 29,447,000Source | 47,370,000Source | 20,670,000Source | 33,057,000Source | 38,418,000Source | 23,747,000Source | 38,307,000Source | 42,369,000Source | 27,130,000Source | 42,159,000Source | 46,200,000Source | 38,729,000Source |
| Liabilities and EquityUSD | 32,352,000Source | 50,390,000Source | 22,660,000Source | 36,577,000Source | 40,995,000Source | 26,097,000Source | 40,577,000Source | 44,829,000Source | 29,562,000Source | 44,954,000Source | 48,635,000Source | 41,661,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,400,000Source | 2,229,000Source | 1,887,000Source | 3,015,000Source | 1,695,000Source | 2,143,000Source | 1,661,000Source | 1,487,000Source | 2,122,000Source | 2,095,000Source | 1,371,000Source | 1,530,000Source |
| Operating Lease, Liability, CurrentUSD | 286,000Source | 357,000Source | 402,000Source | 377,000Source | 351,000Source | 396,000Source | 370,000Source | 344,000Source | 390,000Source | 364,000Source | 338,000Source | 314,000Source |
| Accounts Payable, CurrentUSD | — | — | 540,000Source | — | — | 813,000Source | — | — | 358,000Source | — | — | 648,000Source |
| Operating Lease, Liability, NoncurrentUSD | 505,000Source | 791,000Source | 103,000Source | 505,000Source | 882,000Source | 207,000Source | 609,000Source | 973,000Source | 310,000Source | 700,000Source | 1,064,000Source | 1,402,000Source |
| Additional Financial Items | ||||||||||||
| Short-term InvestmentsUSD | 29,408,000Source | 30,464,000Source | 18,645,000Source | 33,098,000Source | 36,687,000Source | 22,333,000Source | 36,004,000Source | 40,628,000Source | 25,147,000Source | 41,399,000Source | 42,792,000Source | 34,489,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 467,000Source | 651,000Source | 3,420,000Source | 4,141,000Source | 5,196,000Source | 8,994,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | — | — | — | — | -221,000Source | 88,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,238,000Source | -4,018,000Source | -15,568,000Source | -16,838,000Source | -18,858,000Source | -15,619,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 2,770,000Source | 5,201,000Source | 15,856,000Source | 1,335,000Source | -7,868,000Source | -34,554,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 5,000Source | 37,000Source | 33,000Source | 115,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 1,023,000Source | 13,637,000Source | 25,791,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -468,000Source | 1,183,000Source | 1,311,000Source | -1,866,000Source | -935,000Source | -50,173,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 130,000Source |
| Additional Financial Items | ||||||||||||
| DepreciationUSD | — | — | — | — | — | — | — | 100,000Source | 100,000Source | 200,000Source | 200,000Source | 200,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | 22,000Source | 100,000Source | — | — | — | — | — | 49,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -4,539,000Source | -5,642,000Source | -3,600,000Source | -6,694,000Source | -3,849,000Source | -4,503,000Source | -19,472,000Source | -21,819,000Source | -23,516,000Source | -24,669,000Source |
| Nonoperating Income (Expense)USD | — | — | 344,000Source | 528,000Source | 196,000Source | 355,000Source | 213,000Source | 451,000Source | 1,427,000Source | 2,007,000Source | 1,722,000Source | 263,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 22,242,000Source | 8,874,000Source | 46,018,000Source | 55,567,000Source | 56,520,000Source | 48,127,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 782,000Source | — | 25,800,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | 46,000Source | — | — |
| Realized Investment Gains (Losses)USD | — | — | 208,000Source | 428,000Source | 209,000Source | 239,000Source | 238,000Source | 426,000Source | 1,126,000Source | 1,640,000Source | 1,074,000Source | — |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | -39,000Source | 6,000Source | -22,000Source | -79,000Source | -43,000Source | -194,000Source | -391,000Source | -22,000Source | 468,000Source | 49,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment | — | — | — | — | — | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | — | — | 2,298,000Source | 3,311,000Source | 1,720,000Source | 4,158,000Source | 1,951,000Source | 2,397,000Source | 10,918,000Source | 11,577,000Source | 11,655,000Source | 15,018,000Source |
| Operating Income (Loss)USD | — | — | -4,883,000Source | -6,170,000Source | -3,796,000Source | -7,049,000Source | -4,062,000Source | -4,954,000Source | -20,899,000Source | -23,826,000Source | -25,238,000Source | -24,932,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -19,472,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -4,539,000Source | -5,642,000Source | -3,600,000Source | -6,694,000Source | -3,849,000Source | -4,503,000Source | -19,472,000Source | -21,819,000Source | -23,516,000Source | -24,669,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.23Source | -0.35Source | -5.37Source | -11.52Source | -5.89Source | -7.75Source | -33.06Source | -1.27Source | -1.91Source | -2.2Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.23Source | -0.35Source | -5.37Source | -11.52Source | -5.89Source | -7.75Source | -33.06Source | -1.27Source | -1.91Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 20,155,000Source | 16,067,000Source | 671,000Source | 581,000Source | 654,000Source | 581,000Source | 589,000Source | 17,142,000Source | 12,301,000Source | 11,230,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 20,155,000Source | 16,067,000Source | 671,000Source | 581,000Source | 654,000Source | 581,000Source | 589,000Source | 17,142,000Source | 12,301,000Source | — |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 31,000Source | 40,000Source | 136,000Source | 189,000Source | 220,000Source | 212,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | 22,000Source | 100,000Source | — | — | — | — | — | 49,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -19,472,000Source | — | — | — |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | — | 161,000Source |
| Interest Income, OtherUSD | — | — | 175,000Source | 94,000Source | 9,000Source | 195,000Source | 22,000Source | 219,000Source | 692,000Source | 389,000Source | 180,000Source | — |
| Nonoperating Income (Expense)USD | — | — | 344,000Source | 528,000Source | 196,000Source | 355,000Source | 213,000Source | 451,000Source | 1,427,000Source | 2,007,000Source | 1,722,000Source | 263,000Source |
| Realized Investment Gains (Losses)USD | — | — | 208,000Source | 428,000Source | 209,000Source | 239,000Source | 238,000Source | 426,000Source | 1,126,000Source | 1,640,000Source | 1,074,000Source | — |
| Research and Development ExpenseUSD | — | — | 2,585,000Source | 2,859,000Source | 2,076,000Source | 2,891,000Source | 2,111,000Source | 2,557,000Source | 9,981,000Source | 12,249,000Source | 13,583,000Source | 9,914,000Source |
Offerings
Registration 333-298492
Filing attachments
ex107.htm · S-3 · 2026-08-21
Calculation of Filing Fee Tables S-3 enVVeno Medical Corp ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offeri…
Read attachment ↗ex4-5.htm · S-3 · 2026-08-21
Exhibit 4.5 ENVVENO MEDICAL CORPORATION, as ISSUER and [ ], as INDENTURE TRUSTEE INDENTURE Dated as of [ ] TABLE OF CONTENTS Page ARTICLE 1 I DEFINITIONS AND INCORPORATION BY REFERENCE Section Definitions 1 1.01 Section …
Read attachment ↗ex99-1.htm · 8-K · 2026-04-29
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve First-in-Class enVVe system to be evaluated in TAVVE U.S. Pivotal Trial Clinical site activation and patient enrollment expected to commence later this year Large unmet clinical need for approximately 3 million U.S. patients with severe deep Chronic Venous Insufficiency Potential multi-billion-dollar untapped U.S. market Comp…
Read attachment ↗ex99-1.htm · 8-K · 2026-02-04
Exhibit 99.1 enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement Company achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closed Reports Cash and Investments of Approximately $28 million as of the Year Ended December 31, 2025 IRVINE, CA. - February 4, 2026 - enVVeno Medical Corporation (NASDAQ: NVNO) (“enVVeno Medical” or the “Company”), today announced that it has received formal notice from the Listings Qualifications …
Read attachment ↗